Abstract
Introduction Reversing malnutrition-induced impairment of cognition and emotional regulation is a critical global gap. We hypothesize that brain-targeted micronutrient supplemented nutritional rehabilitation in children with moderate acute malnutrition, followed by 2 years micronutrient supplementation will impact on the cognition and emotion regulation of these children.
Methods The primary outcome of this prospective, randomized controlled trial is to study the development of executive functions (EFs) and emotion regulation (ER) in this cohort.
Moderate acute malnourished (MAM; WLZ/WHZ <-2 and ≥-3 z-score, and/or 11.5 cm ≤ MUAC < 12.5cm; n=140)children aged around one year (11m-13m) in Mirpur, Dhaka, Bangladesh will be randomized (1:1) to receive either locally produced Ready to Use Supplementary Food (RUSF) or Enhanced Ready to Use Supplementary Food (E-RUSF) until anthropometric recovery (WLZ/WHZ > -1SD), or for 3 months after enrollment (whichever is earlier). The randomized MAMs groups will be given either Small Quantity Lipid Based Nutrient Supplement (SQLNS) or Enhanced Small Quantity Lipid Based Nutrient Supplement (E-SQLNS), respectively until the end of the 2-year follow up period. Standard psychosocial stimulation will be provided to the MAMs intervention groups. Biological samples will be collected, anthropometric and neurocognitive assessments will be performed at 2 (22m-26m) and 3 (34m-38m) years of age.
Two control groups will be recruited: 1), non-malnourished one-year (11m-13m) old children (WLZ/WHZ score>-1SD; n=70); and 2) three –year (34m-38m) old children (n=70) with untreated MAM (WHZ <-2 and ≥-3 z-score, and/or 11.5≤MUAC<12.5 cm). The 3-year-old MAM reference group will be assessed once and provided with 2 months of nutritional rehabilitation support (RUSF Nutriset’s Plumpy’SupTM).
Ethics and dissemination The study protocol has been reviewed and approved by all the relevant ethical review boards at each research site (icddr,b Bangladesh; University of the West Indies, Kingston Jamaica; and University of Auckland, New Zealand). The results will be disseminated through peer-reviewed publications and national and international scientific conferences.
Protocol version 1 (1/11/2022)
Trial registration number NCT05629624. Registered on November 29, 2022.
Competing Interest Statement
I have read the journal's policy and the authors of this manuscript have the following competing interests: M. Zeilani is employed by Nutriset, who collaborated and produced the enhanced E-RUSF, SQ-NLS and E-SQLNS feed and supplements. However, they had no role in the design or delivery of the trial.
Clinical Trial
ClinicalTrials.gov, study ID number: NCT05629624
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The protocol (registered on ClinicalTrials.gov, study ID number: NCT05629624) was co-developed by researchers from The University of The West Indies, Boston Children’s Hospital, USA, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), and University of Auckland, New Zealand. Ethical approvals were obtained from the Research Review Committee (RRC August 21, 2021) and Ethical Review Committee (ERC) of icddr,b (protocol no: PR-21084 September 21, 2021), Institutional Review Board of Boston Children’s Hospital, USA (for analyses of neuropsychological assessments), University of Auckland, New Zealand (approval AH23922 for analyses of collected biological samples) and University of West Indies (CREC-MN.51, 21/22).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
After the study completes, anonymous post-processed metagenomics sequencing data will be publicly accessible through the Sequence Read Archive on the National Center for Biotechnology Information. Genetic data will be made available through dbgap. De-identified clinical data can be provided for future research upon valid requests submitted to the International Centre for Diarrheal Disease Research, Bangladesh. Requests will have to fall within the original ethics approvals, with appropriate institutional ethics approval. Requestors must consent to a Data Access Agreement, which involves a pledge to solely utilize the data for the designated research proposal and commitments not to make any attempt to identify any individual participants, to securely store and handle the data, and to dispose of the data upon project’s conclusion.
